Genetic Signatures Limited – Panel Receives Application

Takeovers Panel Version 1 original current

Imported from official source

The Panel has received an application from BCAL Diagnostics Limited (BCAL) in relation to the affairs of Genetic Signatures Limited (GSS). Details of the application, as submitted by the applicant, are below. A sitting Panel has not been appointed at this stage and no decision has been made whether to conduct proceedings. The Panel makes no comment on the merits of the application. GSS is an ASX listed company (ASX:GSS) operating in the infectious disease diagnostics sector. The applicant is an ASX listed company (ASX:BDX) and a substantial shareholder of GSS, owning 18.46% of the GSS shares on issue. On 26 August 2026, GSS announced it was in discussions with Microba Life Sciences Limited (ASX: MAP) (MAP) in relation to a potential merger (the Proposed Transaction). The announcement stated that the structure and commercial aspects of the Proposed Transaction were still being considered. On 22 September 2026, GSS announced that the principal commercial terms of the Proposed Transaction had been agreed. The Proposed Transaction was to be implemented by way of a scheme of arrangement under which GSS would acquire 100% of MAP shares and options, with MAP shareholders to o...

This version

Version
1 of 1
Recorded
November 15, 2026 23:33
Change
Initial
Content hash
056932781e1d730a313c10add0cb8f0f
All versions
Revision history

Officially records where a publication came from, not whether it is true. Imported records are reproduced from an organization's own official source.